Exchange: NYSE·Updated 03:52 PM EDT

BSX News

News
all
press releases
Boston Scientific Says Cyberattack Will Impact 2026 Results — Says It Is ‘Unlikely’ To Meet Net Sales Growth, EPS Guidance Ranges
Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.
Stocktwits
More News
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific expects a 2026 earnings miss after a cyberattack disrupted global operations. Manufacturing and shipping are recovering.read more...
Benzinga
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?
MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
Zacks
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
Zacks
Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack...
Yahoo! Finance: News
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
Zacks
Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.read more...
Benzinga
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
Zacks
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
Zacks
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Zacks

Advertisement|Remove ads.